Galantamine Tablet, Film Coated
Product Images NDC 51407-908

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 51407-908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-906-60ol (Galantamine 4 mg)

Label for Galantamine 4 mg film-coated tablets, USP, containing 60 tablets per bottle. The label shows the NDC number 51407-906-60 and indicates the product is prescription only. Marketed by Golden State Medical Supply, Inc. The label includes storage instructions and a note that each tablet contains galantamine hydrobromide USP equivalent to 4 mg galantamine.*

FDA Label Image

51407-907-60ol (Galantamine 8 mg)

Galantamine 8 mg tablets, USP film-coated oral tablets in a 60-tablet package by Golden State Medical Supply, Inc. The label includes storage instructions, dosage reference to prescribing information, safety warnings, and a barcode, with the NDC 51407-907-60.*

FDA Label Image

51407-908-60ol (Galantamine 12 mg)

Label for Galantamine 12 mg tablets USP by Golden State Medical Supply, Inc. The film-coated oral tablets come in a package of 60 tablets, indicated as prescription only. The label includes a barcode, lot, expiration, and serial number fields, dosage strength highlighted in purple, and storage instructions at 25°C with permitted excursions.*

FDA Label Image

Chemical Structure (Galantamine 01)

Chemical structure of galantamine hydrobromide, showing its molecular arrangement including a methoxy group, hydroxyl group, and nitrogen atom as part of its bicyclic framework.*

FDA Label Image

Image Description (Galantamine 02)

A line graph showing the mean change from baseline in ADAS-cog scores over 21 weeks of treatment. The graph compares placebo with three dosages of galantamine (8 mg/day, 16 mg/day, 24 mg/day), illustrating trends of cognitive improvement or decline over time.*

FDA Label Image

Image Description (Galantamine 04)

A bar chart displaying the percentage of patients by CIBIC-plus rating categories ranging from markedly improved to markedly worse. The chart compares placebo and three dosage groups of galantamine (8 mg/day, 16 mg/day, 24 mg/day) across these categories.*

FDA Label Image

Image Description (Galantamine 05)

A line graph depicting the mean change from baseline in ADAS-Cog score over 26 weeks of treatment. The x-axis represents weeks of treatment (0, 3, 13, 26), and the y-axis shows mean change in score, with improvement above zero and decline below zero. Three lines compare treatments: placebo, 24 mg/day, and 32 mg/day doses, illustrating cognitive performance changes over time.*

FDA Label Image

Image Description (Galantamine 06)

A line graph showing cumulative percentage of patients on the y-axis versus ADAS-cog change from baseline on the x-axis. The graph compares three groups: placebo, 24 mg/day, and 32 mg/day dosages of galantamine, illustrating cognitive change over a range from -15 to 15 points.*

FDA Label Image

Image Description (Galantamine 07)

A bar graph showing the percentage of patients rated on the CIBIC-plus scale across different categories from "Markedly Improved" to "Markedly Worse." The graph compares three groups: Placebo, 24 mg/day, and 32 mg/day dosages, with percentage of patients on the vertical axis and CIBIC-plus rating categories on the horizontal axis.*

FDA Label Image

Image Description (Galantamine 08)

A line graph depicting the mean change from baseline in ADAS-Cog scores over 26 weeks of treatment. The graph compares placebo and two dosage groups (24 mg/day and 32 mg/day), showing improvement over time for the 24 mg/day and 32 mg/day groups, and decline in the placebo group.*

FDA Label Image

Image Description (Galantamine 09)

A line graph depicting the cumulative percentage of patients versus ADAS-cog change from baseline. The graph compares three groups: Placebo, 24 mg/day galantamine, and 32 mg/day galantamine, showing cognitive changes over a range from -15 to +15 points with markers for -10, -7, -4 points and no change at zero.*

FDA Label Image

Image Description (Galantamine 10)

A bar graph showing the distribution of patient outcomes based on the CIBIC-plus rating for three groups: placebo, 24 mg/day, and 32 mg/day. The x-axis shows categories from markedly improved to markedly worse, while the y-axis shows the percentage of patients in each category.*

FDA Label Image

Image Description (Galantamine 11)

A line graph showing mean change from baseline in ADAS-cog score over 13 weeks of treatment comparing placebo and 24 or 32 mg/day doses. The vertical axis represents mean (±SE) change with improvement indicated upward, while the horizontal axis shows weeks of treatment at 0, 4, and 13. The graph depicts improvement in the 24 or 32 mg/day group, while placebo shows little change or decline.*

FDA Label Image

Image Description (Galantamine 12)

A cumulative percentage plot comparing ADAS-cog change from baseline between placebo and 24 or 32 mg/day dosing groups. The x-axis shows ADAS-cog change with marked points at -10, -7, -4, and no change, while the y-axis shows the cumulative percentage of patients. Lines represent patient response distribution for placebo and active treatment groups.*

FDA Label Image

Image Description (Galantamine 13)

A bar chart comparing the percentage of patients by CIBIC-plus rating between placebo and Galantamine (24 or 32 mg/day) groups. The x-axis shows CIBIC-plus rating categories from markedly improved to markedly worse, and the y-axis shows the percentage of patients. The chart illustrates patient distribution across these categories for both treatments.*

FDA Label Image

Figure2 (Galantamine03)

A cumulative percentage of patients chart showing ADAS-cog change from baseline on the x-axis ranging from -15 to 15, and cumulative percentage of patients on the y-axis from 0 to 100%. The graph compares placebo and three doses of galantamine (8 mg/day, 16 mg/day, 24 mg/day) with distinct markers. Vertical lines highlight changes at -10, -7, -4 points, and no change, indicating different levels of cognitive change.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.